Association between the use of antibiotics during pregnancy and obesity in 5-year-old children

Chunyu Zhuang1, Xueli Liao2, Mianai Fu3

  • 1Department of Nursing, Haikou Hospital of the Maternal and Child Health, Haikou, China.

Insights

Antibiotic use during pregnancy is linked to a higher body mass index (BMI) in 5-year-old children. This research indicates a 4% increased risk of obesity in children whose mothers used antibiotics during pregnancy.

Area of Science:

  • Pediatrics
  • Obstetrics
  • Public Health

Background:

  • Childhood obesity is a growing epidemic requiring urgent attention.
  • Investigating the impact of prenatal exposures on child health is crucial.

Purpose of the Study:

  • To examine the association between antibiotic use during pregnancy and childhood obesity.
  • To assess the relationship between maternal antibiotic exposure and BMI in 5-year-old Chinese children.

Main Methods:

  • A cohort of 132 children aged 5 years was analyzed.
  • Data included maternal pre-pregnancy BMI, gestational diabetes, smoking, delivery mode, and weight gain.
  • Linear and logistic mixed-effects regression models were employed to assess correlations.

Main Results:

  • Maternal antibiotic use during pregnancy showed a positive correlation with children's BMI (β=0.01, P=0.04).
  • Antibiotic use during pregnancy was associated with a 4% increased risk of obesity in 5-year-old children (OR=1.04, P=0.02).

Conclusions:

  • Prenatal exposure to antibiotics is positively associated with an increased risk of obesity in early childhood.
  • Findings highlight a potential link between maternal antibiotic use and long-term child metabolic health.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
33
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
44
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
787
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
34
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
41
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
57